American Journal on Addictions最新文献_第2页

2025 AAAP Annual Meeting Abstract Submissions Open! 2025年AAAP年会开放摘要投稿！

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70043

引用次数: 0

Pain intensity in patients using extended-release naltrexone or opioid agonists and its effect on extended-release naltrexone treatment outcomes. 使用缓释纳曲酮或阿片类激动剂患者的疼痛强度及其对缓释纳曲酮治疗结果的影响。

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70035

Farid Juya, Kristin K Solli, Line Holtan, Ann-Christin Sannes, Bente Weimand, Anne G Sagen, Jūratė Š Benth, Johannes Gjerstad, Lars Tanum, Jon Mordal

{"title":"Pain intensity in patients using extended-release naltrexone or opioid agonists and its effect on extended-release naltrexone treatment outcomes.","authors":"Farid Juya, Kristin K Solli, Line Holtan, Ann-Christin Sannes, Bente Weimand, Anne G Sagen, Jūratė Š Benth, Johannes Gjerstad, Lars Tanum, Jon Mordal","doi":"10.1111/ajad.70035","DOIUrl":"https://doi.org/10.1111/ajad.70035","url":null,"abstract":"Background and objectives: Extended-release naltrexone (XR-NTX) is an opioid antagonist effective for treating opioid use disorder (OUD). However, concerns about inadequate pain management may limit its use. This study will examine changes in pain intensity in OUD patients choosing XR-NTX compared to opioid agonist treatment (OAT), identify subgroups with distinct pain intensity trajectories, and assess the effect of pain intensity on XR-NTX treatment outcomes (retention, relapse, opioid use, and cravings).Methods: This 24-week study included OUD patients aged 18-65 years opting for XR-NTX (n = 160). Patients receiving OAT (n = 151) served as controls. Pain intensity was measured every 4 weeks for XR-NTX and at baseline and Week 24 for OAT using the numerical pain rating scale-11 (NPRS-11). Data were analyzed with linear mixed models and group-based trajectory modeling.Results: Between baseline and Week 24, XR-NTX participants with low to moderate pain showed a significant reduction in pain intensity, while those with high pain did not. In the OAT group, no significant reduction in pain intensity was observed (from baseline to Week 24). Pain intensity was not associated with XR-NTX treatment outcomes.Discussion and conclusions: Contrary to perception, XR-NTX does not worsen pain intensity, nor did pain intensity affect XR-NTX treatment outcomes.Scientific significance: This study is the first to explore the association between changes in pain intensity and XR-NTX treatment outcomes in OUD patients over a 24-week period. The findings challenge the perception that XR-NTX is less suitable for treating OUD patients with pain.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Call for Review Papers 2025 2025年征稿

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70037

引用次数: 0

Call for Special Issue Papers 2025 征集2025年特刊论文

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70038

引用次数: 0

Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancy. 每月丁丙诺啡储存注射（SUBLOCADE®）用于妊娠期间阿片类药物使用障碍。

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70034

Melinda Ramage, Becky Bishop, Vikki Mangano, Baher Mankabady

{"title":"Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancy.","authors":"Melinda Ramage, Becky Bishop, Vikki Mangano, Baher Mankabady","doi":"10.1111/ajad.70034","DOIUrl":"https://doi.org/10.1111/ajad.70034","url":null,"abstract":"Background and objectives: Untreated opioid use disorder (OUD) in pregnancy is associated with adverse obstetrical outcomes, maternal morbidity, and maternal mortality. This article will inform clinicians about the use of monthly extended-release buprenorphine (BUP-XR, SUBLOCADE®) to treat OUD during pregnancy and postpartum.Methods: We examined the use of monthly BUP-XR during pregnancy in patients with OUD, summarizing case studies (N = 4) from clinical practice, reviewing >5 years of pregnancy and postpartum surveillance data (quantitative [N = 322] and qualitative) and relevant literature in PubMed (N = 4).Results: The clinical practice case studies highlight the experience from four pregnant patients with OUD who received monthly BUP-XR. All four neonates were delivered full-term with normal birthweight, no fetal anomalies, and no medication required for neonatal opioid withdrawal syndrome. Additionally, over 300 pregnancies have been reported through postmarketing surveillance, of which 68 have known outcomes consistent with information described in the product label. Findings from literature, postmarketing surveillance, and clinical practice case studies were consistent with the established safety profile of buprenorphine.Conclusion and scientific significance: This study addresses a lack of knowledge of treatment of pregnant individuals with OUD and draws on relevant experience from prescribers treating patients with monthly BUP-XR during pregnancy and postpartum. These data support consideration of implementing BUP-XR as part of evidence-based practice that prioritizes OUD treatment access, patient stability, and patient choice during the perinatal period. Three sources of data illustrate that the use of monthly BUP-XR during pregnancy has demonstrated no increased risk and is consistent with the established buprenorphine safety profile.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AAAP 36th Annual Meeting & Scientific Symposium - Save the Date AAAP第36届年会暨科学研讨会-保存日期

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70039

引用次数: 0

AAAP Performance and Practice (PIP) Resources AAAP性能和实践（PIP）资源

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-28 DOI: 10.1111/ajad.70040

引用次数: 0

Exploring cannabis as a treatment for chronic pain in a rural Appalachian population. 探索大麻作为阿巴拉契亚农村人口慢性疼痛的治疗方法。

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-19 DOI: 10.1111/ajad.70033

Treah Haggerty, Toni M Rudisill, Patricia Dekeseredy, Abigail Cowher, Cara L Sedney

{"title":"Exploring cannabis as a treatment for chronic pain in a rural Appalachian population.","authors":"Treah Haggerty, Toni M Rudisill, Patricia Dekeseredy, Abigail Cowher, Cara L Sedney","doi":"10.1111/ajad.70033","DOIUrl":"https://doi.org/10.1111/ajad.70033","url":null,"abstract":"Background and objectives: Many cannabis laws include medical use with pain as an indication. However, it is not known the extent of cannabis use for pain, the types of pain treated, and the perceived effectiveness of cannabis for chronic pain in this region. The purpose of this study was to understand cannabis use for pain in West Virginia patients.Methods: Ten thousand chronic pain patients were surveyed, and users and non-users of cannabis were compared.Results: One thousand three hundred fifty-one people responded, with 24% using cannabis. They were in pain for longer, most >10 years. They often used other medications for pain and more often had a previous opioid prescription for pain.Discussions and conclusions: Patients who use cannabis have higher levels of reported pain for longer durations of time than those who do not use cannabis. More information is needed to understand the implications for cannabis use in this population.Scientific significance: Patients with chronic pain who use cannabis have tried multiple treatment modalities, had more types of pain, and often received an opioid prescription.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tobacco use and impulsivity in people with mental illness: A systematic review. 精神疾病患者的烟草使用和冲动：一项系统综述。

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-16 DOI: 10.1111/ajad.70032

Angela Praecht, Shivahn Garvie, Maryam Sorkhou, James MacKillop, Tony P George

{"title":"Tobacco use and impulsivity in people with mental illness: A systematic review.","authors":"Angela Praecht, Shivahn Garvie, Maryam Sorkhou, James MacKillop, Tony P George","doi":"10.1111/ajad.70032","DOIUrl":"https://doi.org/10.1111/ajad.70032","url":null,"abstract":"Background and objectives: Impulsivity is a risk factor for the development and maintenance of tobacco use, especially among individuals with comorbid mental illness, but the nature of this relationship is poorly understood. We systematically examined evidence for the relationship between impulsivity and tobacco use in people with psychiatric disorders.Methods: Following PRISMA guidelines, original peer-reviewed articles published from database inception to July 2024 were searched for using PubMed, Google Scholar, ProQuest, Ovid, and PsycINFO.Results: Of 1192 articles identified, 16 met the inclusion criteria. There was consistent evidence of a positive relationship between tobacco use and impulsivity in schizophrenia (SZ), major depressive disorder (MDD) and bipolar disorder (BD). However, the majority of studies were cross-sectional studies, preventing causal inferences.Discussion and conclusions: Tobacco smoking is robustly associated with impulsivity in people with SZ, MDD, and BD, although causal conclusions cannot be drawn due to methodological limitations of the current literature. Future prospective and experimental studies are needed to ascertain whether impulsivity is a risk factor for smoking, how tobacco use affects impulsivity, and whether impulsivity may be a treatment target for smoking cessation.Scientific significance: To our knowledge, this article is the first comprehensive review of literature, specifically examining the relationship of tobacco smoking and impulsivity among individuals with psychiatric disorders. By highlighting this understudied intersection, our findings provide novel insights into the relationship between smoking behaviors and impulsivity in individuals with mental illness, contributing to more effective treatment strategies and emphasizing the need for tailored interventions to address these co-morbidities.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of cannabis use with major cardiovascular and cerebrovascular events after surgery or interventional procedures. 大麻使用与手术或介入性手术后主要心脑血管事件的关联。

IF 2.5 4区医学

American Journal on Addictions Pub Date : 2025-04-09 DOI: 10.1111/ajad.70029

Sarah Ashrafian, Elena Ahrens, Luca J Wachtendorf, Ricardo Munoz-Acuna, Denys Shay, Aiman Suleiman, Simone Redaelli, Dario von Wedel, Guanqing Chen, Georg Wolff, Kevin P Hill, Maximilian S Schaefer

{"title":"Association of cannabis use with major cardiovascular and cerebrovascular events after surgery or interventional procedures.","authors":"Sarah Ashrafian, Elena Ahrens, Luca J Wachtendorf, Ricardo Munoz-Acuna, Denys Shay, Aiman Suleiman, Simone Redaelli, Dario von Wedel, Guanqing Chen, Georg Wolff, Kevin P Hill, Maximilian S Schaefer","doi":"10.1111/ajad.70029","DOIUrl":"https://doi.org/10.1111/ajad.70029","url":null,"abstract":"Background and objectives: Previous studies reported a predisposition to major adverse cardiovascular or cerebrovascular events (MACCE) in patients consuming cannabis, which might be exacerbated by interventional or surgical procedures. This study investigated the association of nonmedical cannabis use with MACCE after interventional procedures or surgery.Methods: 288,923 adult patients undergoing noncardiac surgery between 2008 and 2020 at a tertiary academic hospital in Massachusetts, United States, were included. The exposure was nonmedical use of cannabis, differentiated into ongoing self-reported recreational use or a diagnosis of cannabis use disorder. The primary outcome was MACCE, defined as ischemic stroke, cardiac arrest, acute heart failure, myocardial infarction, or revascularization within 1 year.Results: Patients with a diagnosis of cannabis use disorder had a higher risk of MACCE (adjusted odds ratio 1.26; 95%CI 1.05-1.51; p = .02). For recreational users, this was dependent on the patient's baseline cardiac risk, based on the revised cardiac risk index (RCRI) class: among patients at high cardiac risk (RCRI class III/IV), recreational cannabis use was associated with increased risk (adjusted odds ratio 1.41; 1.15-1.74; p = .001), while there was no association among patients with a low RCRI class (I/II; adjusted odds ratio 0.87; 0.75-1.02; p = .09).Discussion and conclusions: Patients with a diagnosed cannabis use disorder are at increased risk of post-procedural MACCE, while for recreational users, this association was dependent on patients' baseline cardiac risk.Scientific significance: This study demonstrates the association between cannabis use and MACCE differentiated by type of use and depending on baseline cardiac risk.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0